Jon Scott Jacobsen
Corporate Officer/Principal chez ACLARIS THERAPEUTICS, INC.
Profil
Jon Scott Jacobsen is currently working as the Senior Vice President-Chemistry at Aclaris Therapeutics, Inc. He previously worked as the Director-Chemistry Department & Senior Scientist at Pfizer Inc. and as the Chemistry Director at Aclaris Life Sciences, Inc. Dr. Jacobsen completed his undergraduate degree at Harvey Mudd College and obtained a doctorate degree from the University of California, Irvine.
Postes actifs de Jon Scott Jacobsen
| Sociétés | Poste | Début |
|---|---|---|
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Jon Scott Jacobsen
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Aclaris Life Sciences, Inc.
 Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Directeur Technique/Scientifique/R&D | - |
Formation de Jon Scott Jacobsen
| Harvey Mudd College | Undergraduate Degree |
| University of California, Irvine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| ACLARIS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Aclaris Life Sciences, Inc.
Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Health Services |
